Key Points Medpace's revenue growth was strong last quarter. The company is building up a backlog as the clinical trial sector recovers. Shares of Medpace are up 100% since the beginning of this year. 10 stocks we like better than Medpace › Shares of Medpace (NASDAQ: MEDP) zoomed 13% higher this week as of 11:49 a.m. ET on Friday, according to data from S&P Global Market Intelligence. The clinical research organization that helps pharmaceutical companies perform outsourced research and trial test ...